NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

After Biogen failed with a takeover bid in January, Supernus has swooped in to buy the postpartum depression pill developer.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Surovatamig shows promise, but needs to outperform established therapies such as Blincyto and Aucatzyl.

Ethris has entered a strategic partnership with Thermo Fisher Scientific for providing completely integrated mRNA solution.

Lynozyfic’s global sales are projected to reach $707 million by 2031.